Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Other Non-Current Assets: 2019-2024

Historic Other Non-Current Assets for C4 Therapeutics (CCCC) over the last 6 years, with Dec 2024 value amounting to $3.4 million.

  • C4 Therapeutics' Other Non-Current Assets changed negligibly% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.4 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $3.4 million for FY2024, which is negligibly% changed negligibly from last year.
  • Per C4 Therapeutics' latest filing, its Other Non-Current Assets stood at $3.4 million for FY2024, which was down 0.00% from $3.4 million recorded in FY2023.
  • C4 Therapeutics' Other Non-Current Assets' 5-year high stood at $3.4 million during FY2023, with a 5-year trough of $2.6 million in FY2020.
  • For the 3-year period, C4 Therapeutics' Other Non-Current Assets averaged around $3.4 million, with its median value being $3.4 million (2024).
  • Data for C4 Therapeutics' Other Non-Current Assets shows a peak YoY climbed of 27.24% (in 2021) over the last 5 years.
  • C4 Therapeutics' Other Non-Current Assets (Yearly) stood at $2.6 million in 2020, then rose by 27.24% to $3.3 million in 2021, then remained steady at $3.3 million in 2022, then rose by 5.00% to $3.4 million in 2023, then remained steady at $3.4 million in 2024.